* hepatitis
** HPV
*** definition
DNA virus
*** drug classes
**** nucleoside/nucleotide analogues
**** [#B] immunoglobulins
PEG interferon α-2a
(PEG means polyethylene glycol)
**** viral RNA synthesis inhibitors
*** recommendations
**** first line
entacavir/tenofovir + Peg-interferon α-2a
**** second line
Lamivudine (3TC), telbivudine, and adefovir
** HCV
*** direct acting antivirals :l:
**** NS3-4A protease inhibitors
***** brand
“previr”
***** Simeprevir
****** [#A] brand
Olysio
**** NS-5B RNA polymerase inhibitors
***** suffix
“buvir”
***** Sofosbuvir
****** [#B] brand
Sovaldi
**** NS-5A inhibitors
***** suffix
“asvir”
***** drugs :l:
****** Elbasavir + Grazoprevir
******* [#A] brand
Zepatier
* HIV
** CCR5 receptor antagonists (2007) :l:
*** Maraviroc
**** MOA
- Binds selectively and specifically to chemokine receptor CCR5 necessary for entrance of HIV into CD4+ cells
- Prevents interaction between host cell CCR5 and viral gp120
- inhibits the coreceptor, which causes the adverse drug reactions 
** Fusion Inhibitors (FIs) (2003) :l:
*** Enfuvirtide
** Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) (1987)
*** Zidovudine
*** Lamivudine & Emtricitabine
*** Tenofovoir
*** Abacavir
*** Didanosine
*** Zalcitabine
*** Stavudine
** Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) (1996) :l:
*** Nevirapine
*** Efavirenz
*** Doravirine
**** [#B] brand
Pifeltro
** Integrase inhibitors (INSTIs) (2007) :l:
*** Raltegravir
** Protease Inhibitors (PI) (1995)
*** drugs
**** Saquinavir
**** Atazanavir
**** Darunavir
**** Cobicistat/Ritonavir
*** [#B] complete regimens
**** TODO ARV Combinations slide 62/67; 2019 Mar 7 toward the end
- Juluca: dolutegravir + rilpivirine
